A single amino acid substitution in the activation loop defines the decoy characteristic of VEGFR-1/FLT-1

被引:66
作者
Meyer, RD
Mohammadi, M
Rahimi, N
机构
[1] Boston Univ, Sch Med, Dept Ophthalmol, Boston, MA 02118 USA
[2] Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA
[3] NYU, Sch Med, Dept Pharmacol, New York, NY 10016 USA
关键词
D O I
10.1074/jbc.M506454200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
VEGFR-1 is a kinase-defective receptor tyrosine kinase (RTK) and negatively modulates angiogenesis by acting as a decoy receptor. The decoy characteristic of VEGFR-1 is required for normal development and angiogenesis. To date, there is no molecular explanation for this unusual characteristic of VEGFR-1. Here we show that the molecular mechanisms underlying the decoy characteristic of VEGFR-1 is linked to the replacement of a highly conserved amino acid residue in the activation loop. This amino acid is highly conserved among all the type III RTKs and corresponds to aspartic acid, but in VEGFR-1 it is substituted to asparagine. Mutation of asparagine (Asn1050) within the activation loop to aspartic acid promoted enhanced ligand-dependent tyrosine autophosphorylation and kinase activation in vivo and in vitro. The mutant VEGFR-1 (Asp1050) promoted endothelial cell proliferation but not tubulogenesis. It also displayed an oncogenic phenotype as its expression in fibroblast cells elicited transformation and colony growth. Furthermore, mutation of the invariable aspartic acid to asparagine in VEGFR-2 lowered the autophosphorylation of activation loop tyrosines 1052 and 1057. We propose that the conserved aspartic acid in the activation loop favors the transphosphorylation of the activation loop tyrosines, and its absence renders RTK to a less potent enzyme by disfavoring transphosphorylation of activation loop tyrosines.
引用
收藏
页码:867 / 875
页数:9
相关论文
共 50 条
  • [21] Vascular endothelial growth factor receptor-1 (VEGFR-1/Flt-1): a dual regulator for angiogenesis.
    Shibuya M.
    Angiogenesis, 2006, 9 (4) : 225 - 230
  • [22] Flt-1 (VEGFR-1) negatively regulates blood vessel formation by modulating endothelial cell division.
    Kearney, JB
    Ambler, CA
    Monaco, KA
    Johnson, N
    Rapoport, RG
    Bautch, VL
    DEVELOPMENTAL BIOLOGY, 2001, 235 (01) : 247 - 247
  • [23] VEGFR-1/FLT-1 is induced by protein kinase C and its Ectodomain Cleavage is regulated by glycosylation and metalloproteases
    Raikwar, Nandita S.
    Liu, Kang Z.
    Thomas, Christie P.
    FASEB JOURNAL, 2012, 26
  • [24] P10.01: Effects of VEGFR-1 (FLT-1) Inhibition During Pregnancy on the Uterine Circulation of the Mouse
    G. Osol
    E. Khankin
    A. Karumanchi
    Artery Research, 2011, 5 (4) : 188 - 189
  • [25] Modulation of human NK cell lines by vascular endothelial growth factor and receptor VEGFR-1 (FLT-1)
    Chen, WS
    Kitson, RP
    Goldfarb, RH
    IN VIVO, 2002, 16 (06): : 439 - 445
  • [26] VEGFR-1 (FLT-1) activation modulates acute lymphoblastic leukemia localization and survival within the bone marrow, determining the onset of extramedullary disease
    Fragoso, R
    Pereira, T
    Wu, Y
    Zhu, ZP
    Cabeçadas, J
    Dias, S
    BLOOD, 2006, 107 (04) : 1608 - 1616
  • [27] Placental growth factor (PIGF) and its receptor Flt-1 (VEGFR-1) - Novel therapeutic targets for angiogenic disorders
    Luttun, A
    Tjwa, M
    Carmeliet, P
    LYMPHATIC CONTINUUM: LYMPHATIC BIOLOGY AND DISEASE, 2002, 979 : 80 - 93
  • [28] Expression of VEGFR-1 (Flt-1) in breast cancer is associated with VEGF expression and with node-negative tumour stage
    Schmidt, Melanie
    Voelker, Hans-Ullrich
    Kapp, Michaela
    Dietl, Johannes
    Kammerer, Ulrike
    ANTICANCER RESEARCH, 2008, 28 (3A) : 1719 - 1724
  • [29] VEGFR-1/Flt-1 inhibition increases angiogenesis and improves muscle function in a mouse model of Duchenne muscular dystrophy
    Bosco, Jennifer
    Zhou, Zhiwei
    Gabriels, Sofie
    Verma, Mayank
    Liu, Nan
    Miller, Brian K.
    Gu, Sheng
    Lundberg, Dianna M.
    Huang, Yan
    Brown, Eilish
    Josiah, Serene
    Meiyappan, Muthuraman
    Traylor, Matthew J.
    Chen, Nancy
    Asakura, Atsushi
    De Jonge, Natalie
    Blanchetot, Christophe
    de Haard, Hans
    Duffy, Heather S.
    Keefe, Dennis
    MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT, 2021, 21 : 369 - 381
  • [30] ABSENCE OF MUTATIONS IN THE TYROSINE KINASE AND JUXTAMEMBRANE DOMAINS OF VEGFR-1 (FLT-1) AND VEGFR-2 (KDR) GENES IN CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML)
    Such, E.
    Cervera, J.
    Valencia, A.
    Senent, M. L.
    Gamero, E.
    Mallo, M.
    Collado, R.
    Amigo, V.
    Vicente, A.
    Luno, E.
    Hernandez-Boluda, J. C.
    Andreu, R.
    Arenillas, L.
    Oltra, S.
    Sole, F.
    Sanz, M. A.
    Sanz, G.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 488 - 488